Abstracts was 38.2 years (SD = 12.6) and 62.7% were female. 85.9% of our respondents were born outside Canada and 71.8% were ethnically from Asian areas. Effectiveness of the preventive treatment (Risk of developing active TB after treatment, −0.23, p < 0.001), Risk of developing liver damage (−0.16, p < 0.001), Length of treatment (−0.05, p < 0.001), Risk of developing skin rash (−0.03, p = 0.002), and Risk of developing fatigue (−0.03, p = 0.009) were significant determinants of respondents' choices of preventive treatment. The negative preference estimates revealed that respondents were averse to higher risk of developing active TB, higher risk of developing liver damage, skin rash and fatigue, and longer period of treatment. Frequency of clinic visit was not a significant factor. Respondents' preferences varied according to their socio-demographic characteristics, past experiences of TB, BCG vaccination status, and the reason for tuberculin skin test. CONCLUSIONS: The results suggest that respondents were consistently in favor of LTBI preventive treatment with higher effectiveness, less side effects and shorter length.
1
Pfizer, Inc, New York, NY, USA, 2 Pfizer, Inc, Peapack, NJ, USA OBJECTIVES: To conduct a post-hoc analysis of the time-courses of MNWS item or domain scores (MNWS scores) and weekly point prevalence of abstinence (PVR) during the treatment phase of a previously-published (Aubin et al, 2008 ) randomized open-label clinical trial of varenicline (N = 376) vs. NRT (N = 370). METHODS: Current cigarette smokers, motivated to quit smoking, participated in the trial and completed the MNWS instrument. Descriptive statistics (mean ± standard error) of the MNWS scores from weeks 2 to 7 were computed. Time-course comparisons stratified by PVR were performed, with weekly responders defined by PVR = 0 and nonresponders otherwise. Multivariate repeated-measures mixed-effects regression was conducted for each MNWS domain score as the outcome variable. Covariates included baseline, treatment, patient characteristics, smoking history and PVR. Statistical significance was reached when two-sided p ≤ 0.05. RESULTS: The mean baseline MNWS scores of varenicline vs. NRT were comparable. By PVR, varenicline significantly reduced the mean urge to smoke vs. NRT in weeks 2, 3, 4 and 5 (0.45 ± 0.10; 0.28 ± 0.09; 0.27 ± 0.10; 0.27 ± 0.09, respectively; all p < 0.01) among responders, and in weeks 2 to 6 (0.59 ± 0.13; 0.44 ± 0.14; 0.46 ± 0.16; 0.52 ± 0.18; 0.38 ± 0.17; all p < 0.03) among non-responders. The mean negative affect scores were significantly lower in weeks 2 to 5 and 7 (0.31 ± 0.07; 0.20 ± 0.06; 0.18 ± 0.07; 0.23 ± 0.07; 0.13 ± 0.06; all p < 0.03) among responders and in week 2 (0.22 ± 0.11; p < 0.04) among non-responders. Additionally, restlessness was significantly reduced in weeks 2 to 5 (0.45 ± 0.10; 0.33 ± 0.09; 0.22 ± 0.09; 0.22 ± 0.08; all p < 0.02) among responders and in week 2 (0.42 ± 0.14; p < 0.003) among non-responders, and similarly the reduction of increased appetite (0.38 ± 0.18; p < 0.05) among nonresponders in week 7. CONCLUSIONS: Overall, lower mean patient-reported MNWS scores associated with symptoms of tobacco withdrawal were observed for varenicline than for NRT, reaching statistical significance, particularly among abstainers. Differences in the dynamics of treatment effects along with concomitant abstinence status warrant further bivariate analyses. It is expected that chronic diseases will account for 73% of deaths and 60% of the global diseases by 2020. India is experiencing a fast health transition, in 2005 chronic disease contributed to an estimated 53% of deaths and 44% of disability-adjusted life years lost. Chronic diseases are a serious public health issue, particularly because they require long-term therapy. Asthma, a major chronic disease, has become a cause of global concern in terms of its increasing prevalence, morbidity, and economic impact. Improving access to essential medicines and adherence to standard treatment guidelines can decrease the morbidity and mortality. The present scenario of access to essential medicines and treatment behaviour to asthma in India is investigated. METHODS: Recent studies conducted (2007) (2008) (2009) ) on asthma management and adherence to therapy were analysed. Data on availability and price of two essential medicines for asthma, beclomethasone and salbutamol inhalers was collated from five medicine price studies conducted in five states of India, Haryana, Karnataka, Maharashtra, Rajasthan and Chennai (capital, Tamil Nadu state). RESULTS: Except for Rajasthan no inhalers were on state essential medicine list and were not available in any of the public facility; in Rajasthan these inhalers were available only in public facility of capital city. Results of the asthma management studies indicate poor knowledge regarding treatment of bronchial asthma by prescribers, pharmacists and by patients and asthma is not treated according to standard treatment guidelines. More than 80% patients and/or prescribers are treating acute episodes, rather than focusing on long-term asthma control. Ninety-two percent of patients alter the dose of inhaled corticosteroids after the acute attack. CONCLUSIONS: Since the incidence of chronic diseases are increasing rapidly in India, there is urgent need for improving access to essential medicines, treatment guidelines, policy making, patient & provider education, and resource allocation for chronic diseases, like bronchial asthma.
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PRS37 DRUG UTILIZATION PATTERNS FOR PEDIATRIC ASTHMA IN AMBULATORY CARE SETTINGS
Yang M, Patel A, Aparasu RR University of Houston, Houston, TX, USA OBJECTIVES: This study examined the asthma medications prescribing patterns among pediatric asthma visits in ambulatory care settings in the United States. METHODS: A retrospective cross-sectional analysis of National Ambulatory Medical Care Survey (NAMCS) and the outpatient data of the National Hospital Ambulatory Medical Care Survey (NHAMCS) of year 2006-2007 was conducted involving children aged less than 18 years and diagnosed with asthma (ICD-9-CM 493.XX). The analyses focused on medications based on the guidelines of the National Asthma Education and Prevention Program (NAEPP). Descriptive statistics was used to examine the prescribing pattern. RESULTS: According to NAMCS and NHAMCS, there were18 million (0.87%) physician office visits by children with asthma. Long Acting β2 Agonist was highly prescribed among (57.50%) office visits, followed by Leukotrine Modifiers (29.91%) and Inhaled Corticosteroids (27.88%). Oral Corticosteroids and Short Acting β2 Agonist were prescribed in 15.99%, and 14.18% of office visits, respectively. In terms of individual medicines, Albuterol, was mostly prescribed among 10.43 million visits, followed by Montelukast, 5.42 million visits. Prednisolone was prescribed in 2.71 million visits and Levalbuterol was prescribed in 2.36 million visits. CONCLUSIONS: Long Acting β2 Agonist and Leukotrine Modifiers was the most highly prescribed medication class and Albuterol and Montelukast were highly prescribed individual medications in pediatrics asthma ambulatory care visits in the United States. Care Survey (NHAMCS) were analyzed. Sample data was weighted to provide US national estimates. Adults more than 25 years of age were included in the study and COPD visits were identified (ICD-9-CM: 491,492,496). First line of therapy was defined as prescription of either beta-agonist or anticholinergics. Descriptive weighted analysis was performed to examine the prescribing pattern of drugs and multivariate logistic regression using complex survey design was conducted to identify variation for first line of therapy across sex, race and region, while controlling for age, tobacco use, insurance, metropolitan area, and region. RESULTS: In 2006 -2007 ) ambulatory care visits by adult patients, representing 3.3% of the total ambulatory visits. Of these visits, majority were made by females (59.14%), whites (87.31%) and living in the southern region (44.78%). COPD medications were only prescribed in 42.13% of the visits. Highly prescribed medications were bronchodilators (34.33%), followed by combination therapy (9.66%) and inhaled corticosteroids (2.71%). First line of therapy was prescribed at 25.17% (95% CI: 21.62-28.72) visits: 19.16% visits received beta-agonist and 11.84% visits received anticholinergics. No variation was found across sex, race, and region for the prescription of first line of therapy for COPD. CONCLU-SIONS: Bronchodilators were highly prescribed medication for COPD in outpatient visits. The first line of therapy did not vary significantly across sex, race and region for COPD.
PRS38 DRUG PRESCRIBING PATTERN IN AMBULATORY CARE SETTINGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN 2006-2007
PRS39 ASSESSING DEMOGRAPHIC DISPARITIES IN UTILIZATION OF INHALED CORTICOSTEROIDS AMONG PATIENTS WITH PERSISTENT ASTHMA
Vaidya V, Partha G, Holl S University of Toledo, Toledo, OH, USA OBJECTIVES: To find out demographic factors predicting inhaled corticosteroid utilization among asthma patients. METHODS: The study utilized data from the four-state sample of National Asthma Survey (NAS), sponsored by the National Center for Environmental Health (NCEH), Centers for Disease Control. The study population consisted of patients with persistent asthma as (defined by the symptoms score based on NHLBI guidelines). Frequency distributions were made to characterize the study population. Logistic regression was carried out to determine the odds of reporting use of inhaled corticosteroids across various demographic variables (Age, gender, race, income level, insurance coverage, and disease severity). Data was analyzed using SAS v9.0. RESULTS: Underutilization of inhaled corticosteroids (ICSs) was found to exist in the asthmatic patients as over half of our study population (52.6%,n = 323)did not even report the use of ICSs. Disparities were also found to exist in our study across various variables. Blacks were found to have much lower odds of using ICSs when compared to other races (OR, 0.572; CI, . Black uninsured children also demonstrated similar trends. Patients having some form of
